

1 **Reduced Olfactory Bulb Volume Accompanies Olfactory**
2 **Dysfunction After Mild SARS-CoV-2 Infection:**
3 **The Hamburg City Health Study COVID Program**
4

5 Marvin Petersen, MD^{a#}; Benjamin Becker, MD^{b#}; Maximilian Schell^a, Carola Mayer^a,
6 Felix L. Nägele^a, Elina Petersen, MSc^{c,d}; Raphael Twerenbold, MD^{c,d,e,f}; Götz
7 Thomalla, MD^a; Bastian Cheng, MD^a; Christian Betz, MD^b, Anna S. Hoffmann, MD^b

8 ^a Department of Neurology, University Medical Center Hamburg-Eppendorf,
9 Hamburg, Germany

10 ^b Department of Otorhinolaryngology and Head and Neck Surgery, University Medical
11 Center Hamburg-Eppendorf, Hamburg, Germany

12 ^c Population Health Research Department, University Heart and Vascular Center,
13 Hamburg, Germany

14 ^d Department of Cardiology, University Heart and Vascular Center, Hamburg,
15 Germany

16 ^e German Center for Cardiovascular Research (DZHK), partner site
17 Hamburg/Kiel/Luebeck, Hamburg, Germany

18 ^f University Center of Cardiovascular Science, University Heart and Vascular Center,
19 Hamburg, Germany

20
21 # These authors contributed equally

22
23
24
25
26
27
28
29
30 Total word count of main manuscript: 3000

31

32 **Materials & Correspondence**

33 Correspondence and requests for materials should be addressed to

34 Dr. med. Marvin Petersen

35 Department of Neurology

36 University Medical Center Hamburg-Eppendorf

37 Martinstraße 52, 20246 Hamburg, Germany

38 +4940-7410-59094

39

40 **Key Points**

41 **Question:** Is olfactory dysfunction associated with alterations of the olfactory bulb in
42 individuals who recovered from mild to moderate SARS-CoV-2 infection?

43 **Findings:** 17.5% of investigated individuals exhibited long term olfactory dysfunction.
44 Olfactory bulb volume was lower in individuals with post-acute olfactory dysfunction
45 and predicted long-term olfactory function.

46 **Meaning:** Our results demonstrate the link between olfactory function and olfactory
47 bulb integrity after SARS-CoV-2 infection, rendering olfactory bulb volume a
48 promising surrogate marker of long-term smelling outcomes in COVID-19.

49

50

51 **Abstract**

52 **Importance:** Olfactory dysfunction is a frequent sequel of SARS-CoV-2 infection.

53 Despite its prevalence, the SARS-CoV-2-related pathophysiology of olfactory

54 dysfunction remains not well understood.

55

56 **Objective:** Determine whether long-term olfactory dysfunction in mild to moderate

57 SARS-CoV-2 infection corresponds with structural alteration of the olfactory bulb.

58

59 **Design, Setting and Participants:** Data of non-vaccinated COVID-19 convalescents

60 recruited between 1st March and 31st December 2020 were analyzed. Within the

61 framework of the Hamburg City Health Study COVID Program, participants

62 underwent magnetic resonance imaging (MRI) and neuropsychological testing as

63 well as a structured questionnaire for olfactory function. In addition, olfactory function

64 was assessed at an additional timepoint between 15th March and 15th April 2022

65 including quantitative olfactometric testing with Sniffin' Sticks.

66

67 **Exposure:** SARS-CoV-2 infection confirmed by a positive polymerase chain reaction

68 test (PCR).

69

70 **Main Outcomes and Measures:** Primary study outcomes were olfactory dysfunction

71 and the MRI-based measurement of olfactory bulb volume.

72

73 **Results:** This study included 233 individuals recovered from mainly mild to moderate

74 SARS-CoV-2 infections (44.2% female, age [years], mean \pm SD, 55.79 \pm 7.25).

75 Longitudinal assessment demonstrated a declining prevalence of olfactory

76 dysfunction from 67.1% at acute infection, 21.0% at baseline examination (mean \pm
77 SD, 8.31 ± 2.77 months post infection) and 17.5% at follow-up (mean \pm SD, $21.8 \pm$
78 3.61 months post infection). Participants with post-acute olfactory dysfunction had a
79 significantly lower olfactory bulb volume [mm^3] at scan-time than normally smelling
80 individuals (mean \pm SD, baseline: 40.76 ± 13.08 vs. 46.74 ± 13.66 , $f = 4.07$, $p =$
81 0.046 ; follow-up: 40.45 ± 12.59 vs. 46.55 ± 13.76 , $f = 4.50$, $p = 0.036$). Olfactory bulb
82 volume predicted olfactometric scores at follow-up ($r_{sp} = 0.154$, $p = 0.025$).
83 Performance in neuropsychological testing was not significantly associated with the
84 olfactory bulb volume.

85

86 **Conclusions:** Our work demonstrates the association of olfactory dysfunction and
87 olfactory bulb integrity in a sample of individuals recovered from mainly mild to
88 moderate COVID-19. Olfactory bulb volume was demonstrably lower in individuals
89 with sustained olfactory dysfunction and predicted long-term smelling function
90 longitudinally. Collectively, our results highlight olfactory bulb volume as a surrogate
91 marker that may inform diagnosis and guide rehabilitation strategies in COVID-19.

92

93 **Introduction**

94

95 The coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe
96 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected societies
97 worldwide. Olfactory dysfunction is among the most common symptoms in COVID-19
98 with a reported prevalence of up to 85%.¹⁻⁸ COVID-19 features olfactory dysfunction
99 in varying degrees – e.g., anosmia, hyposmia or parosmia – which occur often before
100 the onset of respiratory symptoms.³ Compared to other COVID-19-related symptoms
101 like cough, fever or fatigue, olfactory dysfunction proved to be more predictive of
102 SARS-CoV-2 infection.^{9,10} Despite its relevance, the understanding of the
103 pathophysiology of SARS-CoV-2-related olfactory dysfunction is still incomplete.

104

105 There is ongoing research in the mechanisms of COVID-19-related olfactory
106 dysfunction. Commonly, anosmia in the absence of rhinorrhea or nasal congestion is
107 described as an early symptom which suggests other causal mechanisms than a
108 common cold with conductive deficits causing olfactory dysfunction.^{3,4,11,12} SARS-
109 CoV-2 might affect the olfactory system at different breakpoints of its trajectory
110 ranging from disruption of sustentacular cells and olfactory sensory neurons situated
111 in the olfactory mucosa to functional disarray of the olfactory cortex.^{13,14} Yet, there is
112 only vague understanding of how these aspects relate to clinical outcomes.

113

114 Magnetic resonance imaging (MRI) provides a promising avenue to investigate the
115 pathomechanistic substrates of olfactory dysfunction in SARS-CoV-2 infection in vivo.
116 Previous MRI studies put emphasis on the integrity of the olfactory bulb (OB) as a
117 structural correlate of olfactory function in general.¹⁵⁻¹⁷ Volume reduction of the OB
118 accompanies olfactory loss in conditions like acute or chronic rhinosinusitis and head

119 trauma.¹⁸ Abnormalities in psychophysical olfactory testing are demonstrably
120 associated with OB volume alterations in health and disease.^{19–21} Furthermore, the
121 duration and degree of olfactory loss is proportional to the OB volume.²² So far,
122 studies relating OB volumetry and olfactory function in COVID-19 rely on case
123 reports and small sample sizes yielding heterogeneous results.^{14,23–27} Therefore,
124 further investigations are warranted.

125

126 Based on previous evidence, we hypothesized that olfactory dysfunction in COVID-
127 19 corresponds with interindividual volumetric differences of the OB. To address this
128 hypothesis, we quantified the OB volume based on structural MRI and performed a
129 longitudinal assessment of olfactory function in a large sample of individuals
130 recovered from mainly mild to moderate COVID-19. As affection of the olfactory
131 system might precede COVID-19-related neuropathology, we additionally probed for
132 a relationship of OB alterations and neuropsychological test score results in an
133 exploratory analysis. With this work we aimed to further the understanding of the
134 effects SARS-CoV-2 exerts on the olfactory system and thus deepen our insight in
135 the pathophysiology underlying the clinical sequelae of COVID-19.

136

137 **Methods**

138

139 **Study population and clinical examination**

140 In this work we investigated data from participants of the Hamburg City Health Study
141 (HCHS) Covid Program with available MRI data. A detailed description of the study
142 design has been published separately.^{28,29} Our reporting complies with the
143 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
144 statement guidelines.³⁰ In brief, citizens of the city of Hamburg, Germany, were
145 considered for enrollment if they met two criteria: (1) a laboratory-confirmed positive

146 polymerase chain reaction (PCR) test for SARS-CoV-2, which was obtained between
147 1st March and 31st December 2020 but at least 4 months prior to study enrollment; (2)
148 age between 45 and 74 years at the time of inclusion. An invitation was issued upon
149 identification via the clinical information system of the University Medical Center
150 Hamburg-Eppendorf or a response to a public call for participation. Recruited
151 participants underwent an extended study protocol of the Hamburg City Health Study
152 (HCHS): besides the standard HCHS work up including MRI and assessment of
153 cognitive function (Trail Making Test B, Word List Recall, Animal Naming Test, Mini
154 Mental State Exam), depressive symptoms (PHQ-9) and quality of life (EQ-5D),
155 participants were required to retrospectively report on disease severity and SARS-
156 CoV-2-associated symptoms via a structured questionnaire.³¹ The presented study
157 was only conducted based on the post-SARS-CoV-2 cohort – i.e., the matched
158 cohort of control subjects as described previously could not be leveraged as the
159 required high-resolution T2-weighted MRI data was not available.^{28,29} To assess the
160 trajectory of olfactory function, participants were reinvited between 15th March and
161 15th April 2022. Follow-up investigations comprised a structured questionnaire
162 regarding olfactory function as well as olfactometric assessment via Sniffin' Sticks
163 Screening 12 test by two trained otorhinolaryngologists (B.B., A.S.H.).^{32,33} The test
164 score ranges from 0 to 12 (0-6: anosmia, 7-10: hyposmia, 11-12: normosmia) and is
165 based on normative information derived from more than 1200 patients assessed with
166 Sniffin' Sticks Screening and olfactive evoked potentials. Eventually, information
167 about olfactory dysfunction from structured questionnaires was available for three
168 timepoints: (1) during the acute infection, (2) at the baseline investigation and (3) at
169 follow-up. MRI and neuropsychological testing were only performed during baseline
170 examination.

171 **Ethics approval**

172 Written informed consent was obtained from all participants. The study was approved
173 by the local ethics committee of the Landesärztekammer Hamburg (State of
174 Hamburg Chamber of Medical Practitioners, PV5131) and conducted complying with
175 the Declaration of Helsinki.³⁴

176 **MRI acquisition**

177 High-resolution 3D T2-weighted images were acquired at baseline on a 3T scanner
178 (MAGNETOM™Skyra, Siemens Healthineers, Erlangen, Germany) with the following
179 sequence parameters: TR=3200 ms, TE=407 ms, 256 axial slices, ST=0.94 mm, and
180 IPR=0.9×0.9mm.

181 **Olfactory bulb segmentation**

182 We performed OB segmentation on high-resolution T2-weighted images leveraging a
183 novel fully-automated deep learning-based pipeline specifically designed for OB
184 volumetry.³⁵ All resulting segmentations underwent visual quality assessment.
185 Exemplary segmentation results are illustrated in *figure 1* as well as *supplementary*
186 *materials S1*. The summed volume of both OBs was used for further analysis.

187 **Statistical analysis**

188 OB volume and olfactometry scores were compared between individuals with and
189 without questionnaire-assessed olfactory dysfunction at different timepoints
190 employing analyses of covariance (ANCOVA). Multiple linear regression analysis was
191 performed for assessing the linear relationship of olfactometry scores, as well as
192 neuropsychiatric scores with OB volume. A further ANCOVA was performed to test
193 whether the OB volume at baseline differed between individuals with sustained
194 olfactory dysfunction at follow-up and those that recovered until then. The association
195 between the time interval from positive PCR to examination was assessed via

196 Spearman correlation. Age, sex and smoking behavior were included as covariates in
197 ANCOVAs and linear models as they represent potential confounders.³⁶ Statistical
198 computations and plotting were performed in Python 3.9.7 harnessing matplotlib
199 (v.3.5.1), numpy (v.1.22.3), pandas (v.1.4.2), pingouin (v.0.5.1) and seaborn
200 (v.0.11.2).^{37–41}

201

202 **Results**

203

204 **Sample characteristics**

205 Data from 233 HCHS Covid Program participants was available for primary analysis.
206 Nine subjects were excluded pre-analysis: 3 since they reported to have had
207 olfactory dysfunction before their SARS-CoV-2 infection, 3 because of a missing OB
208 and 3 because of erroneous segmentations. Thus, data from n=224 participants were
209 available for the final analysis. Sample characteristics are summarized in *table 1*. On
210 average participants were 55.79 ± 7.25 (mean \pm SD) years old, 44.2% were female
211 and 5.4% were current smokers. 8.4% of participants were hospitalized due to
212 COVID-19.

213 **Longitudinal trajectory of olfactory function**

214 The baseline examination happened on average 253 days after the positive PCR test
215 prompting recruitment, the follow-up at 663 days. 143 participants were available at
216 follow-up. Of these, 67.1% (n=96) described olfactory dysfunction during the acute
217 phase of infection, 21.0% (n=30) at the baseline examination and 17.5% (n=25) at
218 follow-up (*figure 2a*). Assessment of olfactory dysfunction severity via the visual
219 analogue scale resulted in a coherent trajectory: 7.62 ± 2.76 (acute infection), 3.79
220 ± 1.78 (baseline), 2.96 ± 2.10 (follow-up).

221 **Olfactometry**

222 To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks
223 Screening 12 test was performed on participants at follow-up. Olfactometry scores at
224 follow-up were 10.18 ± 1.78 (mean \pm SD). Participants with self-reported olfactory
225 dysfunction at the acute infection did not differ from normally smelling participants
226 regarding olfactometry scores at follow-up (mean \pm SD, 10.04 ± 1.97 vs. 10.46 ± 1.31 ,
227 $\eta^2_p=0.01$, $p=0.211$; *figure 2b*). Yet, participants with olfactory dysfunction at baseline
228 had lower olfactometric scores than normally smelling individuals (mean \pm SD, $8.67 \pm$
229 2.62 vs. 10.58 ± 1.22 , $\eta^2_p=0.19$, $p<0.005$) and the same applied for participants
230 impaired at follow-up (mean \pm SD, 8.40 ± 2.74 vs. 10.56 ± 1.22 , $\eta^2_p=0.22$, $p<0.005$).

231 **Olfactory bulb volume and olfactory function**

232 The mean OB volume was 45.53 ± 12.85 mm³. The ANCOVA yielded no significant
233 group difference in OB volume at acute infection between individuals with and
234 without olfactory dysfunction (mean \pm SD, 45.85 ± 12.92 vs. 45.21 ± 15.16 , $\eta^2_p=0.00$,
235 $p=0.837$; *figure 2c*). Individuals with self-reported sustained olfactory dysfunction at
236 baseline and at follow-up had significantly lower OB volume than normally smelling
237 subjects at that time (mean \pm SD, baseline: 40.76 ± 13.08 vs. 46.74 ± 13.66 ,
238 $\eta^2_p=0.03$, $p=0.046$; follow-up: 40.45 ± 12.59 vs. 46.55 ± 13.76 , $\eta^2_p=0.03$, $p=0.036$).
239 In participants with olfactory dysfunction lower OB volume was accompanied by a
240 shorter time-period between a positive PCR for SARS-CoV-2, signifying the timepoint
241 of acute SARS-CoV-2 infection, and the baseline examination ($r_{sp}=0.161$, $p=0.016$;
242 *figure 2d*).

243 **Longitudinal prediction of olfactory function**

244 OB volume derived from MRI at baseline was significantly linearly associated with
245 olfactometry scoring at follow-up ($r_{sp}=0.154$, $p=0.025$; *figure 2e*). Participants with

246 sustained olfactory dysfunction at follow-up had lower OB volume at baseline (mean
247 \pm SD, 40.64 \pm 12.83 vs. 47.58 \pm 12.58, $\eta^2_p=0.06$, $p=0.018$; *figure 2f*) than those that
248 had recovered by the time of reassessment.

249 **Clinical analysis**

250 To further explore potential clinical implications of our findings, correlations of OB
251 volume and neuropsychological cognitive test scores and psychiatric test scores
252 were performed. To summarize, no significant associations of OB volume and scores
253 of the Trail Making Test B ($r_{sp}=0.014$, $p=0.722$), Animal Naming Test ($r_{sp}=-0.090$,
254 $p=0.069$), Word List Recall Test ($r_{sp}=-0.050$, $p=0.587$), Mini Mental State Exam ($r_{sp}=-$
255 0.025 , $p=0.689$), PHQ-9 ($r_{sp}=0.098$, $p=0.404$) and EQ-5D ($r_{sp}=-0.009$, $p=0.306$) were
256 found. Corresponding visualizations are displayed in *supplementary materials S2*.

257

258 **Discussion**

259

260 We report on an association of OB volume and olfactory dysfunction in a large
261 sample of mainly mildly to moderately affected COVID-19 convalescents.
262 Longitudinal assessment demonstrated sustained olfactory dysfunction up to two
263 years after acute infection. Participants suffering from olfactory dysfunction beyond
264 acute infection had a significantly lower OB volume at baseline than normally
265 smelling individuals. Moreover, OB volume was predictive for olfactometric
266 performance in the Sniffin' Sticks test 22 months after the acute infection as well as
267 for the binary outcome of recovery from olfactory dysfunction at follow-up.
268 Neuropsychological test performances were not significantly associated with OB
269 volume. Taken together, our findings suggest that lower volume of the OB may be a
270 promising surrogate marker of smelling function in COVID-19 at post-acute disease
271 stages.

272

273 Its frequency and the concomitant effects on quality of life render olfactory
274 dysfunction a burdensome symptom of COVID-19. Our 2-year longitudinal
275 assessment of olfactory function provided insights about time-dependent
276 development of these symptoms. At acute infection, the proportion of participants
277 reporting olfactory dysfunction was 67.1% which is coherent with previous study
278 reports ranging from 30% to 85%.^{1-4,6,7} After the acute infection, the prevalence
279 decreased to 21% at the baseline examination (on average 253 days post infection)
280 and 17.5% at follow-up (on average 664 days post infection; *figure 2a*). These
281 numbers support previous literature finding high rates of long term olfactory
282 dysfunction in COVID-19.⁴²⁻⁴⁴ Of note, a recent meta-analysis reports persistent
283 olfactory dysfunction in less patients (11.6%; 95% confidence interval 5.2% to
284 23.9%).⁴⁵ We attribute this difference to design differences with respect to our work:
285 the studies included in the meta-analysis also considered young adults (>18 years)
286 possibly exhibiting higher regenerative capacity as well as recent SARS-CoV-2
287 variants demonstrably affecting patient olfaction less severely than the wild type
288 variant mainly prevalent at the pandemic onset.⁴⁶ Overall, these findings indicate that
289 although most former COVID-19 patients completely recover, subjective olfactory
290 dysfunction persisted in relevant proportion of individuals.

291

292 To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks
293 Screening 12 test was performed at follow-up. Participants suffering from olfactory
294 dysfunction beyond the acute infection, plausibly showed significantly lower
295 olfactometry scores than normally smelling or recovering subjects (*figure 2b*).
296 Collectively, our results support previous evidence of sustained olfactory dysfunction

297 in around 20% of patients underscoring the possible long lasting burden following a
298 SARS-CoV-2 infection.^{6,43}

299

300 Olfactory dysfunction is demonstrably accompanied by lower OB volume in many
301 otorhinolaryngological conditions like post-infectious olfactory disorder, head trauma
302 as well as acute and chronic rhinosinusitis.¹⁸ In line with this notion, our work showed
303 a lower OB volume in individuals with sustained olfactory dysfunction after the acute
304 SARS-CoV-2 infection indicating COVID-19-related OB atrophy (*figure 2c*). Thus, our
305 results corroborate previous reports derived from case studies and small samples
306 suggesting lower OB volume in SARS-CoV-2-induced olfactory dysfunction.^{23–26}

307

308 Previous reports demonstrated an inverse correlation between OB volume and the
309 duration of symptoms in post-infectious olfactory disorder suggesting its predictive
310 capacity.²² To further investigate this, we related the OB volume with olfactometry
311 scores which were acquired approximately 1 year after the MRI. Notably, the OB
312 volume predicted olfactometry scores at follow-up (*figure 2e*). Yet, the observed
313 correspondence was of a rather low degree, indicating that further determinants of
314 long-term olfactory dysfunction should be considered. Possibly, MRI assessment
315 closer to the acute infection would have resulted in the observation of stronger
316 effects. Furthermore, OB volume was higher in participants in which the smelling
317 sense fully recovered until follow-up compared to those with sustained olfactory
318 dysfunction (*figure 2f*). Hence, the OB volume appears to be a predictor of recovery
319 from olfactory dysfunction, i.e., potentially capturing the severity of damage SARS-
320 CoV-2 exerts on the olfactory system. Interestingly, individuals exhibited higher OB
321 volume the longer the time interval between the positive PCR and the MRI was
322 (*figure 2d*). This might indicate that an increasing OB volume may reflect recovery of

323 olfactory function. However, longitudinal imaging assessment is warranted here.
324 Taken together, these findings suggest that a lower OB volume indicates more
325 severe disruption of the olfactory system and predict persistent olfactory dysfunction
326 in COVID-19 patients. Therefore, the OB might serve as a promising diagnostical
327 target for prognosis assessment and even therapeutical monitoring of olfactory
328 dysfunction in COVID-19.

329

330 There are multiple potential mechanisms that might explain the observed link
331 between olfactory dysfunction and OB dysintegrity. In the olfactory mucosa, olfactory
332 sensory neurons (OSN) – sensing molecular signatures as odor information – as well
333 as supporting epithelial cells (sustentacular cells) ensure proper sense of smell.
334 Sustentacular cells express angiotensin-converting enzyme 2 (ACE-2) and appear to
335 be a major infection target of the virus.^{13,47} As they support OSN in a glial-like
336 fashion, impairment of sustentacular cells is considered to contribute to COVID-19-
337 related olfactory dysfunction.⁴⁸ How OSN are affected by SARS-CoV-2 is
338 controversial. Discussed mechanisms are neurotropism, affection by an impaired
339 support system and damage caused by the immune response to the virus.^{13,48,49}
340 Recent analyses failed to detect signs of neurotropism and neural invasion through
341 SARS-CoV-2 challenging the notion of the olfactory system serving the virus as an
342 entry point.^{48,50,51} As the OB serves as a relay for projections from the OSN,
343 volumetric reductions might occur as an effect of indirect OSN affection - e.g., via
344 inflammation or microvasculopathy – rather than direct damage from the virus leading
345 to reduced tissue integrity.⁵¹ Taking the link between OB integrity and long-term
346 olfactory function into account, OB volume might serve as an indicator of severe
347 structural disruption of the olfactory system which corresponds with unfavorable

348 outcomes. Nonetheless, further longitudinal neuroimaging research is warranted to
349 support this notion.

350

351 By now, COVID-19 is recognized to cause post-acute neurological and psychiatric
352 symptoms like executive dysfunction, fatigue, anxiety, depression and sleep
353 impairment.⁵²⁻⁵⁶ Coherent with these observations, a comprehensive MRI analysis on
354 COVID-19 convalescents from the UK Biobank has shown widespread gray matter
355 volume reductions in areas receiving projections from the olfactory cortex.⁵³ Its
356 evident exposition to deleterious SARS-CoV-2 effects renders the OB a candidate
357 indicator of COVID-19-related neuropathology beyond the olfactory system. Thus, we
358 tested whether the OB volume is associated with results of neuropsychological test
359 scores. OB volume showed no significant association with tests of cognitive function
360 (Trail Making Test B, Word List Recall, Animal Naming Test), depressive symptoms
361 (Patient Health Questionnaire-9, PHQ-9) and quality of life (EQ-5D). Consequently,
362 pathology of the olfactory system might be disjunct to non-olfaction-related
363 neuropathology in SARS-CoV-2 infection. Nonetheless, our findings might be partially
364 attributable to the overall mild to moderate disease course captured in our sample
365 resulting in negative results. Further investigations of determinants of neurological
366 and psychiatric sequelae of COVID-19 are necessary.

367

368 The strengths of this work lie in its considerable sample size; high quality imaging
369 and phenotypical data; a modern fully-automated MRI-based segmentation of the OB
370 enabling volumetry at scale; olfactory assessment at different time points post
371 infection, including quantitative olfactory testing (at follow-up) providing longitudinal
372 information for up to 2 years. Yet, this study has some limitations. First, MRI
373 acquisition and olfactometry with Sniffin' sticks were performed only at one timepoint,

374 which makes it difficult to completely address pre-infectious group differences. For
375 instance, our results could partially be explained by individuals with lower OB volume
376 being more susceptible to olfactory dysfunction caused by SARS-CoV-2 infection.
377 Previous work hypothesizes that smaller OB volume and pre-existing reduced
378 number of olfactory receptor neurons increased the patient's vulnerability to develop
379 post-infectious olfactory loss. With less functional tissue existing in the first place,
380 damage to existing sensory cells might lead to more pronounced olfactory
381 dysfunction.⁵⁷ Here, evidence from future longitudinal studies is warranted. As more
382 severely impaired individuals might be more motivated and thus more likely to
383 participate in our study than the average population, our results could possibly be
384 influenced by our recruitment strategy. Lastly, the different SARS-CoV-2 strains
385 appear to differ in terms of olfactory dysfunction frequency and intensity. Our study
386 lacks information about SARS-CoV-2 strains rendering it incapable to address inter-
387 strain differences. However, the investigation started at an early stage of the
388 pandemic most likely soothing the problem of different COVID-19 strains and
389 vaccinations as confounders.

390

391 **Conclusion**

392

393 In this work, we performed an assessment of OB volumetry as a neuroimaging
394 marker of olfactory dysfunction in patients recovered from mainly mild to moderate
395 COVID-19. By revealing an alteration of the OB in participants with olfactory
396 dysfunction, our results highlight the relevance of the olfactory system in the overall
397 pathophysiology of the disease. However, a connection between OB volume and
398 neuropsychological signs of COVID-19 could not be established. Collectively, these
399 results demonstrate that the OB is a promising target for assessment of olfactory

400 dysfunction in COVID-19 potentially facilitating diagnosis and informing therapy-

401 related decisions.

402

403 **Acknowledgments**

404 We describe contributions to the paper using the CRediT contributor role taxonomy.

405 Conceptualization: M.P., A.S.H.; Data Curation: M.P., B.B., M.S., C.M., F.N., A.S.H.;

406 Formal analysis: M.P.; Funding acquisition: G.T., B.C., C.B., A.S.H.; Investigation:

407 M.P., B.B., M.S., C.M., F.N., E.P., R.T., G.T., B.C., C.B., A.S.H.; Methodology: M.P.;

408 Software: M.P.; Supervision: C.B., A.S.H.; Visualization: M.P.; Writing—original draft:

409 M.P., B.B.; Writing—review & editing: M.P., B.B., M.S., C.M., F.N., E.P., R.T., G.T.,

410 B.C., C.B., A.S.H.

411 Data access: M.P., B.B., and A.S.H. had full access to all the data in the study and

412 take responsibility for the integrity of the data and the accuracy of the data analysis.

413

414 The authors wish to acknowledge all participants of the Hamburg City Health Study

415 and cooperation partners, patrons and the Deanery from the University Medical

416 Center Hamburg—Eppendorf for supporting the Hamburg City Health Study. Special

417 thanks applies to the staff at the Epidemiological Study Center for conducting the

418 study. The participating institutes and departments from the University Medical

419 Center Hamburg-Eppendorf contribute all with individual and scaled budgets to the

420 overall funding. The Hamburg City Health Study is also supported by Amgen, Astra

421 Zeneca, Bayer, BASF, Deutsche Gesetzliche Unfallversicherung (DGUV), DIFE, the

422 Innovative medicine initiative (IMI) under grant number No. 116074 and the

423 Fondation Leducq under grant number 16 CVD 03., Novartis, Pfizer, Schiller,

424 Siemens, Unilever and “Förderverein zur Förderung der HCHS e.V.”. The publication

425 has been approved by the Steering Board of the Hamburg City Health Study.

426 GT has received fees as consultant or lecturer from Acandis, Alexion, Amarin, Bayer,

427 Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and

428 Stryker outside the submitted work. The remaining authors declare no conflicts of
429 interest.

430 This work was supported by grants from the German Research Foundation
431 (Deutsche Forschungsgemeinschaft, DFG), Schwerpunktprogramm (SPP) 204 –
432 project number 454012190 – and Sonderforschungsbereich (SFB) 936 – project
433 number 178316478 – Project C2 (M.P., C.M., G.T., and B.C.).

434 Data will be made available on reasonable request from any qualified investigator
435 after evaluation of the request by the Steering Board of the HCHS. Analysis code and
436 documentation is publicly available on GitHub ([https://github.com/csi-](https://github.com/csi-hamburg/CSIframe/blob/main/pipelines/obseg/obseg.sh)
437 [hamburg/CSIframe/blob/main/pipelines/obseg/obseg.sh](https://github.com/csi-hamburg/CSIframe/blob/main/pipelines/obseg/obseg.sh), [https://github.com/csi-](https://github.com/csi-hamburg/CSIframe/wiki/Olfactory-bulb-segmentation)
438 [hamburg/CSIframe/wiki/Olfactory-bulb-segmentation](https://github.com/csi-hamburg/CSIframe/wiki/Olfactory-bulb-segmentation) and [https://github.com/csi-](https://github.com/csi-hamburg/2022_petersen_ob_postcovid)
439 [hamburg/2022_petersen_ob_postcovid](https://github.com/csi-hamburg/2022_petersen_ob_postcovid)).

440

441 **References**

442

- 443 1. von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in
444 COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic
445 Differences. *ACS Chem Neurosci*. 2020;11(19):2944-2961.
446 doi:10.1021/acscchemneuro.0c00460
- 447 2. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and
448 Assessment of an Olfactory Route to Brain Infection. *Neuroscientist*. 2021;27(6):582-603.
449 doi:10.1177/1073858420956905
- 450 3. Cooper KW, Brann DH, Farruggia MC, et al. COVID-19 and the Chemical Senses:
451 Supporting Players Take Center Stage. *Neuron*. 2020;107(2):219-233.
452 doi:10.1016/j.neuron.2020.06.032
- 453 4. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions
454 as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-
455 19): a multicenter European study. *Eur Arch Otorhinolaryngol*. 2020;277(8):2251-2261.
456 doi:10.1007/s00405-020-05965-1
- 457 5. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and Complete Olfactory Loss of Function
458 as a Possible Symptom of COVID-19. *JAMA Otolaryngology–Head & Neck Surgery*.
459 2020;146(7):674-675. doi:10.1001/jamaoto.2020.0832
- 460 6. Lechien JR, Chiesa-Estomba CM, Beckers E, et al. Prevalence and 6-month recovery of
461 olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med*.
462 2021;290(2):451-461. doi:10.1111/joim.13209
- 463 7. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste
464 Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. *Mayo*
465 *Clinic Proceedings*. 2020;95(8):1621-1631. doi:10.1016/j.mayocp.2020.05.030
- 466 8. Parma V, Ohla K, Veldhuizen MG, et al. More Than Smell-COVID-19 Is Associated With
467 Severe Impairment of Smell, Taste, and Chemesthesis. *Chem Senses*. 2020;45(7):609-
468 622. doi:10.1093/chemse/bjaa041
- 469 9. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell
470 dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020;10(8):944-950.
471 doi:10.1002/alr.22587
- 472 10. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to
473 predict potential COVID-19. *Nat Med*. 2020;26(7):1037-1040. doi:10.1038/s41591-020-
474 0916-2
- 475 11. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia in COVID-
476 19 patients: Single-center experience on 72 cases. *Head Neck*. 2020;42(6):1252-1258.
477 doi:10.1002/hed.26204

- 478 12. Ahmed AK, Sayad R, Mahmoud IA, et al. "Anosmia" the mysterious collateral damage of
479 COVID-19. *J Neurovirol*. Published online March 5, 2022. doi:10.1007/s13365-022-01060-
480 9
- 481 13. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as
482 a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci*.
483 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5
- 484 14. Esposito F, Mario Cirillo, Rosa De Micco, et al. Olfactory loss and brain connectivity after
485 COVID -19. *Human Brain Mapping*. Published online January 27, 2022.
486 doi:10.1002/hbm.25741
- 487 15. Haehner A, Rodewald A, Gerber JC, Hummel T. Correlation of Olfactory Function With
488 Changes in the Volume of the Human Olfactory Bulb. *Archives of Otolaryngology–Head &
489 Neck Surgery*. 2008;134(6):621-624. doi:10.1001/archotol.134.6.621
- 490 16. Lu R, Aziz NA, Reuter M, Stöcker T, Breteler MMB. Evaluation of the Neuroanatomical
491 Basis of Olfactory Dysfunction in the General Population. *JAMA Otolaryngology–Head &
492 Neck Surgery*. 2021;147(10):855-863. doi:10.1001/jamaoto.2021.2026
- 493 17. Das S. Olfactory Bulb Volume—A Novel Preclinical Biomarker for Smell Loss and
494 Neurodegenerative Disease. *JAMA Otolaryngology–Head & Neck Surgery*.
495 2021;147(10):864-865. doi:10.1001/jamaoto.2021.2038
- 496 18. Hummel T, Urbig A, Huart C, Duprez T, Rombaux P. Volume of olfactory bulb and depth
497 of olfactory sulcus in 378 consecutive patients with olfactory loss. *J Neurol*.
498 2015;262(4):1046-1051. doi:10.1007/s00415-015-7691-x
- 499 19. Rombaux P, Mouraux A, Bertrand B, Nicolas G, Duprez T, Hummel T. Retronasal and
500 orthonasal olfactory function in relation to olfactory bulb volume in patients with
501 posttraumatic loss of smell. *Laryngoscope*. 2006;116(6):901-905.
502 doi:10.1097/01.mlg.0000217533.60311.e7
- 503 20. Rombaux P, Weitz H, Mouraux A, et al. Olfactory function assessed with orthonasal and
504 retronasal testing, olfactory bulb volume, and chemosensory event-related potentials.
505 *Arch Otolaryngol Head Neck Surg*. 2006;132(12):1346-1351.
506 doi:10.1001/archotol.132.12.1346
- 507 21. Rombaux P, Martinage S, Huart C, Collet S. Post-infectious olfactory loss: a cohort study
508 and update. *B-ENT*. 2009;5 Suppl 13:89-95.
- 509 22. Yao L, Yi X, Pinto JM, et al. Olfactory cortex and Olfactory bulb volume alterations in
510 patients with post-infectious Olfactory loss. *Brain Imaging Behav*. 2018;12(5):1355-1362.
511 doi:10.1007/s11682-017-9807-7
- 512 23. Chiu A, Fischbein N, Wintermark M, Zaharchuk G, Yun PT, Zeineh M. COVID-19-induced
513 anosmia associated with olfactory bulb atrophy. *Neuroradiology*. 2021;63(1):147-148.
514 doi:10.1007/s00234-020-02554-1

- 515 24. Altunisik E, Baykan AH, Sahin S, Aydin E, Erturk SM. Quantitative Analysis of the Olfactory
516 System in COVID-19: An MR Imaging Study. *AJNR Am J Neuroradiol*. 2021;42(12):2207-
517 2214. doi:10.3174/ajnr.A7278
- 518 25. Güney B, Bacaksızlar Sarı F, Özdemir MY, Çullu N, Doğan E, Togan T. Changes in olfactory
519 bulb volume and olfactory sulcus depth in the chronic period after COVID-19 infection.
520 *Acta Otolaryngol*. 2021;141(8):786-790. doi:10.1080/00016489.2021.1946138
- 521 26. Tsigvoulis G, Fragkou PC, Lachanis S, et al. Olfactory bulb and mucosa abnormalities in
522 persistent COVID-19-induced anosmia: a magnetic resonance imaging study. *Eur J*
523 *Neurol*. 2021;28(1):e6-e8. doi:10.1111/ene.14537
- 524 27. Frosolini A, Parrino D, Fabbris C, et al. Magnetic Resonance Imaging Confirmed Olfactory
525 Bulb Reduction in Long COVID-19: Literature Review and Case Series. *Brain Sciences*.
526 2022;12(4):430. doi:10.3390/brainsci12040430
- 527 28. Petersen EL, Goßling A, Adam G, et al. Multi-organ assessment in mainly non-
528 hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study
529 COVID programme. *European Heart Journal*. Published online January 6, 2022:ehab914.
530 doi:10.1093/eurheartj/ehab914
- 531 29. Petersen M, Nägele FL, Mayer C, et al. Brain imaging and neuropsychological assessment
532 of individuals recovered from mild to moderate SARS-CoV-2 infection. Published online
533 July 9, 2022:2022.07.08.22277420. doi:10.1101/2022.07.08.22277420
- 534 30. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
535 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
536 studies. *Lancet*. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
- 537 31. Petersen M, Nägele FL, Mayer C, et al. Brain network architecture constrains age-related
538 cortical thinning. *NeuroImage*. 2022;264:119721.
539 doi:10.1016/j.neuroimage.2022.119721
- 540 32. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction.
541 *Rhinol Suppl*. 2017;54(26):1-30. doi:10.4193/Rhino16.248
- 542 33. Hummel T, Welge-Lüssen A. Assessment of olfactory function. *Adv Otorhinolaryngol*.
543 2006;63:84-98. doi:10.1159/000093752
- 544 34. Petersen M, Frey BM, Schlemm E, et al. Network Localisation of White Matter Damage in
545 Cerebral Small Vessel Disease. *Scientific Reports*. 2020;10(1):9210. doi:10.1038/s41598-
546 020-66013-w
- 547 35. Estrada S, Lu R, Diers K, et al. Automated olfactory bulb segmentation on high
548 resolutional T2-weighted MRI. *NeuroImage*. 2021;242:118464.
549 doi:10.1016/j.neuroimage.2021.118464
- 550 36. Fitzek M, Patel PK, Solomon PD, et al. Integrated age-related immunohistological
551 changes occur in human olfactory epithelium and olfactory bulb. *J Comp Neurol*.
552 2022;530(12):2154-2175. doi:10.1002/cne.25325

- 553 37. Caswell TA, Droettboom M, Lee A, et al. matplotlib/matplotlib: REL: v3.5.2. Published
554 online May 3, 2022. doi:10.5281/zenodo.6513224
- 555 38. Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. *Nature*.
556 2020;585(7825):357-362. doi:10.1038/s41586-020-2649-2
- 557 39. Reback J, McKinney W, jbrockmendel, et al. pandas-dev/pandas: Pandas 1.0.3. Published
558 online March 18, 2020. doi:10.5281/zenodo.3715232
- 559 40. Vallat R. Pingouin: statistics in Python. *JOSS*. 2018;3(31):1026. doi:10.21105/joss.01026
- 560 41. Waskom ML. seaborn: statistical data visualization. *Journal of Open Source Software*.
561 2021;6(60):3021. doi:10.21105/joss.03021
- 562 42. Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, et al. Sociodemographic
563 Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory
564 Dysfunction. *JAMA Network Open*. 2022;5(9):e2230637.
565 doi:10.1001/jamanetworkopen.2022.30637
- 566 43. Boscolo-Rizzo P, Hummel T, Hopkins C, et al. High prevalence of long-term olfactory,
567 gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-
568 control study with one-year follow-up using a comprehensive psychophysical evaluation.
569 *Rhinology*. 2021;59(6):517-527. doi:10.4193/Rhin21.249
- 570 44. Lucidi D, Molinari G, Silvestri M, et al. Patient-reported olfactory recovery after SARS-
571 CoV-2 infection: A 6-month follow-up study. *Int Forum Allergy Rhinol*. 2021;11(8):1249-
572 1252. doi:10.1002/alr.22775
- 573 45. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in
574 patients with covid-19: meta-analysis with parametric cure modelling of recovery curves.
575 *BMJ*. 2022;378:e069503. doi:10.1136/bmj-2021-069503
- 576 46. Klimek L, Hagemann J, Hummel T, et al. Olfactory dysfunction is more severe in wild-type
577 SARS-CoV-2 infection than in the Delta variant (B.1.617.2). *World Allergy Organization*
578 *Journal*. 2022;15(6):100653. doi:10.1016/j.waojou.2022.100653
- 579 47. Chen M, Shen W, Rowan NR, et al. Elevated ACE-2 expression in the olfactory
580 neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and
581 replication. *Eur Respir J*. 2020;56(3):2001948. doi:10.1183/13993003.01948-2020
- 582 48. Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-
583 CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. *Cell*.
584 2021;184(24):5932-5949.e15. doi:10.1016/j.cell.2021.10.027
- 585 49. Clara B, Audrey SA, Ophélie AG, et al. *Neutrophils Initiate the Destruction of the Olfactory*
586 *Epithelium during SARS-CoV-2 Infection in Hamsters*. *Immunology*; 2022.
587 doi:10.1101/2022.03.15.484439

- 588 50. Khan M, Clijsters M, Choi S, et al. Anatomical barriers against SARS-CoV-2 neuroinvasion
589 at vulnerable interfaces visualized in deceased COVID-19 patients. *Neuron*.
590 2022;110(23):3919-3935.e6. doi:10.1016/j.neuron.2022.11.007
- 591 51. Ho CY, Salimian M, Hegert J, et al. Postmortem Assessment of Olfactory Tissue
592 Degeneration and Microvasculopathy in Patients With COVID-19. *JAMA Neurol*.
593 Published online April 11, 2022. doi:10.1001/jamaneurol.2022.0154
- 594 52. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19
595 neurology: clinical, radiological and laboratory findings. *Brain*. 2020;143(10):3104-3120.
596 doi:10.1093/brain/awaa240
- 597 53. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain
598 structure in UK Biobank. *Nature*. Published online March 7, 2022:1-17.
599 doi:10.1038/s41586-022-04569-5
- 600 54. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study
601 Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020;324(6):603-
602 605. doi:10.1001/jama.2020.12603
- 603 55. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients
604 discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-232.
605 doi:10.1016/S0140-6736(20)32656-8
- 606 56. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of
607 COVID-19. *Nature*. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9
- 608 57. Patterson A, Hähner A, Kitzler HH, Hummel T. Are small olfactory bulbs a risk for
609 olfactory loss following an upper respiratory tract infection? *Eur Arch Otorhinolaryngol*.
610 2015;272(11):3593-3594. doi:10.1007/s00405-015-3524-x
- 611

612 **Figure captions**

613 *Figure 1:* Exemplary 3D visualization of olfactory bulb segmentation results.

614 Volumetric visualization of the left and right olfactory bulb (highlighted) and
615 surrounding brain areas. a) coronal, anterior-posterior; b) axial, inferior-superior; c)
616 sagittal, right-left.

617 *Figure 2:* Association of olfactory bulb volume and olfactory function. a) Trajectory of
618 olfactory function along timepoints. Blue dots indicate proportion of individuals with
619 olfactory dysfunction. Gray dots show the average impairment as operationalized by
620 the visual analogue scale. b) Group differences of olfactometry scores at follow-up
621 between participants with and without olfactory dysfunction at different timepoints. As
622 found with respect to olfactory bulb volume, olfactometry scores at follow-up were
623 significantly lower in individuals that exhibited olfactory dysfunction during both
624 examination timepoints but not during the acute infection. c) Group differences of
625 olfactory bulb volume at baseline between participants with and without olfactory
626 dysfunction with respect to different timepoints. Olfactory bulb volume at baseline
627 was significantly lower in individuals that exhibited olfactory dysfunction during both
628 examination timepoints but not during the acute infection. d) Association of the time
629 interval from positive PCR to examination and olfactory bulb volume. A smaller
630 interval was significantly associated with lower olfactory bulb volume. e) Linear
631 associations between olfactory bulb volume and olfactometry scores. A low olfactory
632 bulb volume at baseline was significantly associated with a lower olfactometry score
633 at follow-up. f) Group differences of olfactory bulb volume between participants with
634 sustained olfactory dysfunction at follow-up and those with recovered olfaction to that
635 point. Olfactory bulb volume was significantly lower in participants with sustained
636 olfactory dysfunction. Abbreviations: η_p^2 = partial eta squared indicating the effect

637 size as provided by the analysis of covariance, p = p-value, r_{sp} = spearman

638 correlation coefficient, PCR = polymerase chain reaction, T1 = at baseline, T2 = at

639 follow-up.

640

641

642 **Tables**

643 **Table 1. Characteristics of Post-SARS-CoV-2 Individuals**




| | |
|---|---------------------|
| Demographics | |
| Age in years, mean \pm SD | 55.79 \pm 7.25 |
| Female sex at birth, % | 44.2 |
| Education in years, mean \pm SD | 15.83 \pm 2.52 |
| Current smokers, % | 5.4 |
| Allergic rhinitis, % | 33.3 |
| Diabetes, % | 4.4 |
| COVID-19 | |
| Days between first positive SARS-CoV-2 PCR test and baseline (T1), mean \pm SD | 253.15 \pm 84.46 |
| Days between first positive SARS-CoV-2 PCR test and follow-up (T2), mean \pm SD | 663.51 \pm 109.74 |
| Hospitalization, % | 8.4 |
| Olfaction and olfactory bulb volume | |
| Subjective olfactory dysfunction at acute infection, % | 67.1 |
| Olfactory dysfunction severity (VAS), acute infection, mean \pm SD | 7.62 \pm 2.76 |
| Subjective olfactory dysfunction, T1, % | 21.0 |
| Olfactory dysfunction severity (VAS), T1, mean \pm SD | 3.79 \pm 1.78 |
| Subjective olfactory impairment, T2, % | 17.5 |
| Olfactory dysfunction severity (VAS), T2, mean \pm SD | 2.96 \pm 2.10 |
| Olfactometry score, T2, mean \pm SD | 10.18 \pm 1.78 |
| Olfactory bulb volume in mm ³ , T1, mean \pm SD | 45.53 \pm 12.85 |
| Neuropsychological scores | |
| Trail Making Test B, T1, mean \pm SD | 69.96 \pm 24.84 |

| | |
|---|-------------------|
| Word List Recall Test, T1, mean \pm SD | 8.51 \pm 1.67 |
| Animal Naming Test, T1, mean \pm SD | 28.25 \pm 6.05 |
| Mini Mental State Exam, T1, mean \pm SD | 28.42 \pm 1.24 |
| Patient Health Questionnaire 9, T1, mean \pm SD | 3.54 \pm 3.69 |
| EQ5D, T1, mean \pm SD | 80.74 \pm 14.42 |


644

645 *Abbreviations:* PCR = polymerase chain reaction, post-SARS-CoV-2 = individuals
646 who have recovered from a severe acute respiratory coronavirus type 2 infection, SD
647 = standard deviation, T1 = at baseline, T2 = at follow-up.


648




a)




b)




c)



d)



e)



f)

